Don't Miss

Just Published: Payer Insights: Hepatitis C
Gain insights into what US healthcare payers really think about HCV drug pricing, Solvadi, the growing and frighteningly undefined patient population, limited clinical/outcomes data, poor patient adherence and education - and how can industry positively help and respond. Learn more.

ISS calls on Allergan to allow shareholder vote on any upcoming "buyout-blocking" acquisitions